| |
IR-XR post48a |
IR-IR post48b |
XR-XR post48c |
Total |
| Number of patients, n (%) |
130 (100) |
13 (100) |
276 (100) |
419 (100) |
| Baseline HIV-1 RNA, copies/mL,d,e n (%) |
| <50 |
120 (92.3) |
12 (92.3) |
263 (95.3) |
395 (94.3) |
| ≥50 |
10 (7.7) |
1 (7.7) |
13 (4.7) |
24 (5.7) |
| Baseline CD4+ T-cell counts, cells/mm,d |
| n |
129 |
13 |
276 |
418 |
| Mean |
571.9 |
595.0 |
559.2 |
564.2 |
| SD |
202.8 |
330.1 |
212.8 |
213.7 |
| Baseline CD4+ T-cell counts, cells/mm,d n (%) |
| >50 to 200 |
2 (1.5) |
0 (0.0) |
6 (2.2) |
8 (1.9) |
| >200 to 350 |
13 (10.0) |
2 (15.4) |
38 (13.8) |
53 (12.6) |
| >350 to <400 |
11 (8.5) |
0 (0.0) |
19 (6.9) |
30 (7.2) |
| ≥400 |
103 (79.2) |
11 (84.6) |
213 (77.2) |
327 (78.0) |
| Missing |
1 (0.8) |
0 (0.0) |
0 (0.0) |
1 (0.2) |
| History of AIDS-defining illness, n (%) |
| No |
105 (80.8) |
8 (61.5) |
200 (72.5) |
313 (74.7) |
| Yes |
25 (19.2) |
5 (38.5) |
76 (27.5) |
106 (25.3) |
Note: IR=immediate-release; NVP=nevirapine; XR=extended-release.
a Patients randomized to NVP IR and elected to change to NVP XR after week 48.
b Patients randomized to NVP IR and who chose to remain on NVP IR after week
48.
c Patients randomized to NVP XR who elected to remain on NVP XR after week 48.
d Baseline values are calculated as the average of the last 2 measurements prior to
the start of randomized treatment.
eHIV-1 RNA viral load is based on TaqMan assay results. |
